- Drug Pipelines
- April 2025
- 400 Pages
Global
From €4489EUR$5,000USD£3,823GBP
- Report
- July 2024
- 120 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- May 2025
- 150 Pages
Global
From €4355EUR$4,850USD£3,708GBP
- Report
- March 2025
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- March 2025
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- February 2025
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- December 2024
- 200 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- December 2024
- 200 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- October 2024
- 200 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- August 2024
- 140 Pages
Global
From €2837EUR$3,160USD£2,416GBP
€3547EUR$3,950USD£3,020GBP
- Report
- October 2024
- 200 Pages
Global
From €4443EUR$4,949USD£3,784GBP
- Report
- August 2024
- 41 Pages
Global
From €893EUR$995USD£761GBP
- Newsletter
- June 2025
Global
€2689EUR$2,995USD£2,290GBP
- Report
- October 2024
- 83 Pages
Global
From €4355EUR$4,850USD£3,708GBP
- Report
- January 2025
- 142 Pages
Asia Pacific
From €2918EUR$3,250USD£2,485GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3053EUR$3,400USD£2,600GBP
€3591EUR$4,000USD£3,058GBP
- Report
- October 2024
- 134 Pages
North America
From €3053EUR$3,400USD£2,600GBP
€3591EUR$4,000USD£3,058GBP
- Report
- July 2024
- 108 Pages
North America
From €3098EUR$3,450USD£2,638GBP
- Report
- July 2024
- 112 Pages
Europe
From €3098EUR$3,450USD£2,638GBP
- Report
- June 2024
- 120 Pages
North America
From €3474EUR$3,869USD£2,958GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more